Enzyme inhibition studies evaluate a compound’s inhibitory effect on drug-metabolizing enzymes to predict the potential for drug-drug interactions that may increase toxicity or reduce therapeutic effect of concomitant medications. To learn more about this service, visit our Enzyme Inhibition contract service page.
With over 3500 respondents, only 4% of respondents said they had never experienced any repercussions from postponing these studies...
In preclinical development, a drug will be evaluated for potential to cause a drug-drug interaction (DDI) using in vitro experiments and then calculations that...
Highlights from the recent webinar presented by our newest expert consultant, Dr. Pallavi Limaye In her recent webinar (now available for...
In its most recent in vitro drug interaction guidance update, the US Food and Drug Administration (FDA) emphasized harmony with the...
1. Collect high-quality data to make informed, confident go/no go decisions for moving your drug candidate forward If you need...
Beyond the need for evidence that a drug works, Food and Drug Administration (FDA) and other regulatory bodies around the...
Though there is no ‘roadmap’ spelling out required studies to achieve regulatory approval for clinical entry, a drug candidate’s metabolism...
Test systems for DMPK in vitro studies are part of the very foundation of our company. Our labs were borne of...
That is the question. . . Knowing the answer may save you time and money Good Laboratory Practices (GLP) are...
If you have concerns about how your compound may affect UDP-glucuronosyltransferase (UGT) induction and/or inhibition when combined with other therapeutic...
Understand which transporters are involved in a drug’s absorption, distribution & excretion Originally posted on Labiotech.EU How can you build the...
XenoTech scientists published a paper in Drug Metabolism and Disposition evaluating Ketoconazole and its alternative clinical CYP3A4-5 inhibitors as inhibitors of drug...